Ampio Pharmaceuticals.

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Ampio Pharmaceuticals. sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials none currently recruiting 8 completed top decile by trial count

Ampio Pharmaceuticals.: 12 sponsored US clinical trials, none currently recruiting.

Ampio Pharmaceuticals. sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 5 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Osteoarthritis of the Hand, with 1 trials.

Top-decile sponsor footprint

Ampio Pharmaceuticals. ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 6/100

8 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (66.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

12 total, page 1 of 1

COMPLETED Phase 1

A Study to Evaluate Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID)

NCT04880161

TERMINATED Phase 2

Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen

NCT04839965

TERMINATED Phase 2

A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19

NCT04868890

COMPLETED Phase 1

Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress

NCT04606784

COMPLETED Phase 1

Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation

NCT04456452

TERMINATED Phase 3

Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee.

NCT03988023

TERMINATED Phase 3

Open Label Extension to Assess the Safety of Long-Term Treatment With Ampion for Severe Osteoarthritis (OA) of the Knee

NCT03349645

COMPLETED Phase 3

AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee

NCT03182686

COMPLETED Phase 1

AP-011 Study to Evaluate the Safety of a Single Intra-articular Injection of Ampion™ for Arthritis of the Basal Thumb Joint

NCT02762760

COMPLETED Phase 3

A Study to Evaluate the Efficacy & Safety of an Intra-Articular Ampion Injection for Pain of Osteoarthritis of the Knee

NCT02556710

COMPLETED Phase 3

A Multiple Injection Study Evaluating Safety and Efficacy of Ampion in Osteoarthritis

NCT02242435

COMPLETED Phase 1

A Study to Evaluate Safety of Three Intra-articular Injections of Ampion in the Knee of Adults With Osteoarthritis Pain

NCT02184156

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 2
Phase 3 5

Therapeutic Areas

How the Ampio Pharmaceuticals. archive is shaped

12 indexed studies, none listed as recruiting (0% open); 8 completed (67%).

Phase mix: 5 late (III/IV) vs 7 early (I/II) (balanced across stages).

Top condition: Osteoarthritis of the Hand (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Ampio Pharmaceuticals.: archived-pipeline peers nationwide

Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Ampio Pharmaceuticals. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20% Total trials Recruiting share Ampio Pharmaceuticals.Alachua Government ServicesAllergy TherapeuticsAngiodynamicsApnimed10xBio22nd Century Group23andMe3-C Institute for Social Development
Ampio Pharmaceuticals. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Ampio Pharmaceuticals. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Ampio Pharmaceuticals. page

12 registered trials is a research-attention snapshot, not an endorsement of Ampio Pharmaceuticals. or any single study.

  • None of Ampio Pharmaceuticals.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Osteoarthritis of the Hand is the condition Ampio Pharmaceuticals. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Osteoarthritis of the Hand trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Ampio Pharmaceuticals. pipeline card: 12 registered trials from official public datasets.Report a data error.